We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca (AZ) and the University of Oxford have presented new data from a “pooled analysis” of phase 3 trials evaluating COVID-19 vaccine AZD1222 at two different dose regimens, demonstrating an average efficacy of 70.4 percent. Read More
China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon. Read More
Inovio has dosed the first participant in the phase 2 segment of its phase 2/3 trial evaluating COVID-19 vaccine candidate INO-4800, funded by the Department of Defense (DoD). Read More
Less than a month after receiving an Emergency Use Authorization (EUA) for rheumatoid arthritis drug Olumiant (baricitinib) to treat COVID-19, Eli Lilly is facing questions about the drug’s efficacy in treating the pandemic disease. Read More
Eli Lilly and healthcare company UnitedHealth are working together to conduct a pragmatic study of the American pharma titan’s COVID-19 antibody treatment, bamlanivimab (LY-CoV555), a therapy that received Emergency Use Authorization (EUA) from the FDA nearly a month ago. Read More
Moderna is preparing to launch a new phase 2/3 trial in the U.S. to assess its promising coronavirus vaccine in adolescent participants aged 12 to 17, though it’s not yet clear when it will start enrolling volunteers. Read More
AstraZeneca’s (AZ) late-stage U.S. coronavirus vaccine trial is likely to have efficacy data in January that could be enough for the company to request Emergency Use Authorization (EUA), Operation Warp Speed’s chief adviser Moncef Slaoui said this week. Read More